FUNDAMENTALS · Fundamentals · US Healthcare

Absci (ABSI) Fundamentals 2026 — Revenue Analysis | SniperIQ

Absci (ABSI) is a US-listed Healthcare company in Biotechnology with a market capitalization of

.4B, trading at $8.24 on the NASDAQ. This SniperIQ fundamentals page covers Absci's valuation, profitability (net margin -6450.8%), revenue (
M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.4B
Net Margin-6450.8%
Revenue (FY25)
M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Absci's market cap?

Absci (ABSI) has a market capitalization of approximately

.4B, trading at $8.24 on the NASDAQ. Market cap moves with the live share price.

What is Absci's P/E ratio?

Absci's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Absci?

Absci runs a net profit margin of -6450.8%, a gross margin of -1316.9%, and an operating margin of -7000.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Absci generate?

Absci reported revenue of

M for fiscal year 2025, with net income of -
15M and earnings per share (EPS) of -0.84. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Absci pay a dividend?

Absci does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Absci financially healthy?

Absci carries a debt-to-equity ratio of 0.03x and a current ratio of 6.59x, with a market beta of 2.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Absci a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Absci (ABSI) the key facts are: market cap

.4B, revenue
M, 52-week range 2.24-12.055. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Absci's full fundamentals live

Get Absci's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Taysha Gene Therapies (TSHA) fundamentals · Phibro Animal Health (PAHC) fundamentals · Thomson Medical Group (A50) fundamentals · Nektar Therapeutics (NKTR) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons